Advanced search
Publication Cover
Expert Review of Hematology Volume 17, 2024 - Issue 8
Submit an article Journal homepage
145
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Quality of life considerations in myelodysplastic syndrome: not only fatigue

Pasquale NiscolaHematology Unit, Sant’Eugenio Hospital, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2226-6518View further author information
ORCID Icon,
Valentina GianfeliciHematology Unit, Sant’Eugenio Hospital, Rome, ItalyView further author information
,
Marco GiovanniniHematology Unit, Sant’Eugenio Hospital, Rome, ItalyView further author information
,
Daniela PiccioniHematology Unit, Sant’Eugenio Hospital, Rome, ItalyView further author information
,
Carla MazzoneHematology Unit, Sant’Eugenio Hospital, Rome, ItalyView further author information
&
Paolo de FabritiisHematology Unit, Sant’Eugenio Hospital, Rome, ItalyView further author information
Pages 407-410 | Received 12 Dec 2022, Accepted 05 Jul 2024, Published online: 12 Jul 2024

References

  • Liu Z, Xu X, Ding K, et al. Quality of life considerations and management in patients with myelodysplastic syndrome. Expert Rev Hematol. 2023 Oct;11(11):1–12. doi: 10.1080/17474086.2023.2268837
  • Oliva EN, Platzbecker U, Fenaux P, et al. Targeting health-related quality of life in patients with myelodysplastic syndromes - current knowledge and lessons to be learned. Blood Rev. 2021 Nov;50:100851. doi: 10.1016/j.blre.2021.100851
  • Efficace F, Al Essa W, Platzbecker U. Health-related quality of life profile of newly diagnosed patients with myelodysplastic syndromes by age, sex, and risk group: a real-world study by the GIMEMA. Hemisphere. 2023 Aug 30;7(9):e944. doi: 10.1097/HS9.0000000000000944
  • Niscola P, Gianfelici V, Giovannini M, et al. Latest insights and therapeutic advances in myelodysplastic neoplasms. Cancers (Basel). 2024 Apr 19;16(8):1563. doi: 10.3390/cancers16081563
  • Gamper EM, Cottone F, Sommer K, et al. The EORTC QLU-C10D detected clinical known group differences in myelodysplastic syndromes more efficiently than the EQ-5D-3L. J Clin Epidemiol. 2021 Sep;137:31–44. doi: 10.1016/j.jclinepi.2021.03.015
  • Brownstein CG, Daguenet E, Guyotat D, et al. Chronic fatigue in myelodysplastic syndromes: looking beyond anemia. Crit Rev Oncol Hematol. 2020 Oct;154:103067. doi: 10.1016/j.critrevonc.2020.103067
  • Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018 Jun;32(6):1380–1392. doi: 10.1038/s41375-018-0089-x
  • Abel GA, Hebert D, Lee C, et al. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 Jul 25;7(14):3506–3515. doi: 10.1182/bloodadvances.2022009000
  • Molga A, Wall M, Chhetri R, et al. Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. J Geriatr Oncol. 2020 Jan;11(1):114–120. doi: 10.1016/j.jgo.2019.02.002
  • Luskin MR, Cronin AM, Owens RL, et al. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 May;177(4):562–566. doi: 10.1111/bjh.14573
  • Chen Y, Wang J, Ma J, et al. Clinical significance of prognostic nutritional index in myelodysplastic syndrome. Hematology. 2023 Dec;28(1):2161209. doi: 10.1080/16078454.2022.2161209
  • Kanehira D, Koinuma M, Kato T, et al. Relationship between low pretreatment geriatric nutritional risk index and poor tolerability of azacitidine in patients with myelodysplastic syndromes. Ann Nutr Metab. 2020;76(6):405–412. doi: 10.1159/000513542
  • Takada E, Nakamura N, Kaneda Y, et al. Impact of skeletal muscle depletion on patients with myelodysplastic syndrome treated with azacitidine. Hematol Rep. 2024 Feb 28;16(1):114–124. doi: 10.3390/hematolrep16010012
  • Schuler MK, Hentschel L, Göbel J, et al. Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome pilot study. Leuk Res. 2016 Aug;47:128–135. doi: 10.1016/j.leukres.2016.05.022
  • Buckstein RJ. Integrating patient-centered factors in the risk assessment of MDS. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):373–380. doi: 10.1182/hematology.2019000041

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.